ZA200903134B - Modified soluble FGF receptor FC fusions with improved biological activity - Google Patents

Modified soluble FGF receptor FC fusions with improved biological activity

Info

Publication number
ZA200903134B
ZA200903134B ZA200903134A ZA200903134A ZA200903134B ZA 200903134 B ZA200903134 B ZA 200903134B ZA 200903134 A ZA200903134 A ZA 200903134A ZA 200903134 A ZA200903134 A ZA 200903134A ZA 200903134 B ZA200903134 B ZA 200903134B
Authority
ZA
South Africa
Prior art keywords
fusions
biological activity
fgf receptor
improved biological
modified soluble
Prior art date
Application number
ZA200903134A
Inventor
Mark Nesbit
Beatrice Cameron
Francis Blanche
Sylvie Sordello
Celine Nicolazzi
Marc Trombe
Original Assignee
Centelion
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centelion filed Critical Centelion
Publication of ZA200903134B publication Critical patent/ZA200903134B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ZA200903134A 2006-11-28 2007-11-28 Modified soluble FGF receptor FC fusions with improved biological activity ZA200903134B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06291824 2006-11-28

Publications (1)

Publication Number Publication Date
ZA200903134B true ZA200903134B (en) 2010-08-25

Family

ID=37908084

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200903134A ZA200903134B (en) 2006-11-28 2007-11-28 Modified soluble FGF receptor FC fusions with improved biological activity

Country Status (5)

Country Link
CN (1) CN101589145B (en)
DO (1) DOP2009000115A (en)
ES (1) ES2366160T3 (en)
UY (1) UY30749A1 (en)
ZA (1) ZA200903134B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2640377B1 (en) * 2010-11-15 2018-12-26 Five Prime Therapeutics, Inc. Fgfr1 extracellular domain combination therapies
CN102219860B (en) * 2011-05-20 2012-09-12 烟台荣昌生物工程有限公司 FGFR-Fc fusion protein and applications thereof
KR102132149B1 (en) * 2012-07-24 2020-07-09 더 트러스티스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕 Fusion proteins and methods thereof
US9957313B2 (en) 2013-03-15 2018-05-01 Remegen, Ltd. FGFR-FC fusion proteins and the use thereof
RU2021107536A (en) * 2015-11-23 2021-07-02 Файв Прайм Терапьютикс, Инк. FGFR2 INHIBITORS SEPARATELY OR IN COMBINATION WITH IMMUNOSTIMULATING AGENTS IN THE TREATMENT OF CANCER

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6656728B1 (en) * 1999-02-08 2003-12-02 Chiron Corporation Fibroblast growth factor receptor-immunoglobulin fusion

Also Published As

Publication number Publication date
ES2366160T3 (en) 2011-10-17
DOP2009000115A (en) 2010-02-15
CN101589145A (en) 2009-11-25
CN101589145B (en) 2013-11-13
UY30749A1 (en) 2008-07-03

Similar Documents

Publication Publication Date Title
IL198480A0 (en) Modified soluble fgf receptor fc fusions with improved biological activity
HK1222168A1 (en) Compounds with (substituted phenyl)-propenal moiety, their derivatives, biological activity, and use thereof ()-
EP2214700A4 (en) Semi-synthetic glp-1 peptide-fc fusion constructs, methods and uses
EP2379594B8 (en) Human cgrp receptor binding antibodies
EP2367793B8 (en) Gpr120 receptor agonists and uses thereof
EP2077757A4 (en) Means for sampling animal blood
EP2018416A4 (en) Disposable bioreactor
EP2313435A4 (en) Fibroblast growth factor receptor 3 (fgfr3) binding proteins
EP2083846A4 (en) N-terminal fgf variants having increased receptor selectivity and uses thereof
EP1854410A4 (en) Biosensor coupled with needle
EP2161287A4 (en) OPTIMIZED TACI-Fc FUSION PROTEINS
SI2303891T1 (en) Pyrazolo-quinazolines as protein kinase activity modulators
EP2006296A4 (en) Crustacean-derived protein having antifreeze activity
EP2376099A4 (en) Yl-based insulin-like growth factors exhibiting high activity at the insulin receptor
GB201001635D0 (en) Active blood vessel sleeve
GB0707129D0 (en) Fermenter monitor
EP2017355A4 (en) Gene associated with arteriosclerotic disease, and use thereof
EP1984862A4 (en) Plasmon tomography
ZA200903134B (en) Modified soluble FGF receptor FC fusions with improved biological activity
EP2219660A4 (en) Modified il-4 mutein receptor antagonists
GB0602922D0 (en) Catalyst preparation
ZA201000215B (en) Sequential enzyme delivery system
EP2102231A4 (en) Improved expression system for recombinant human arginase i
ZA200809732B (en) Single use syringe
AP2009004801A0 (en) Single use self-disabling syringe